Bahsoun Aymen, Fakih Yeva, Zareef Rana, Bitar Fadi, Arabi Mariam
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Pediatric Department, American University of Beirut Medical Center, Beirut, Lebanon.
Front Med (Lausanne). 2023 Aug 14;10:1202504. doi: 10.3389/fmed.2023.1202504. eCollection 2023.
The wide and rapid spread of the COVID-19 pandemic has placed an unanticipated burden on the global healthcare sector. This necessitated a swift response from the international community to reach a solution. Efforts were made in parallel to develop preventative and therapeutic modalities. Since then, drug repurposing has blossomed as a potentially rapid resolution and has included various agents with anti-viral and anti-inflammatory properties. Corticosteroids, being potent anti-inflammatory agents, have been placed under extensive investigation. Various trials have recorded the beneficial outcome of corticosteroids in decreasing the mortality and morbidity of COVID-19. With the high pace of escalating events, the quality and study design of clinical trials are varied. Therefore, this study aims to explore the role of corticosteroids in COVID-19 disease. It inspects the molecular, pharmacologic, and clinical proof behind this theory.
新冠疫情的广泛迅速传播给全球医疗保健部门带来了意想不到的负担。这使得国际社会必须迅速做出反应以找到解决方案。同时人们努力开发预防和治疗方法。从那时起,药物重新利用作为一种可能快速解决问题的方法蓬勃发展,其中包括各种具有抗病毒和抗炎特性的药物。皮质类固醇作为强效抗炎药,已受到广泛研究。各种试验记录了皮质类固醇在降低新冠死亡率和发病率方面的有益结果。随着事件升级的速度加快,临床试验的质量和研究设计各不相同。因此,本研究旨在探讨皮质类固醇在新冠疾病中的作用。它考察了这一理论背后的分子、药理学和临床证据。